Turnstone Biologics Corp. (TSBX) Stock Analysis

What Turnstone Biologics Corp. does

Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.

Key metrics

ETFs linked to TSBX

Broad-market and Healthcare sector ETFs an investor holding Turnstone Biologics Corp. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TSBX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Turnstone Biologics Corp.?

Turnstone Biologics Corp. trades under the ticker TSBX on NASDAQ.

Which exchange is TSBX listed on?

TSBX is listed on NASDAQ.

What sector does Turnstone Biologics Corp. operate in?

Turnstone Biologics Corp. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TSBX in a portfolio?

PortView shows TSBX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.